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INTRODUCTION
Antitumor agents used in treating cancer cause 
a great number of toxic side effects (1). They result 
in decreasing the dose of the chemotherapeutic agent 
and also in therapy discontinuation. Therefore, it is 
clinically important to create new effective agents, 
the function of which is to stop the growth of tumor 
cells and to limit the toxic effects. A promising strat-
egy developed to that end is the implementation of 
polymeric pharmaceutical systems (2,3). These sys-
tems have been developed to provide: 1) drugs that 
attack tumor cells; 2) local delivery and maintenance 
of drug therapeutic concentration in the target tis-
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sue for a longer period; 3) reduction of systemic side 
effects.
ADVANTAGES OF POLYMERIC 
PHARMACEUTICAL SYSTEMS 
Drug delivery systems are used by millions of 
patients for the treatment of different diseases. The 
use of such systems have led to the formation of new 
or the improvement of already existing therapies. A 
strategy to suppress the toxicity of drug substanc-
es involves their binding with polymers (4-11). The 
idea of covalent binding of a low molecular weight 
drug to a hydrophilic polymer carrier in order to in-
crease its therapeutic effect was suggested by Helmut 
Ringsdorf (4) in 1975 for the first time. This model 
not only provides for a change in the pharmacokinet-
ics of the bound drug but also enables the attack of 
the target tissue by introduction of a guiding residue 
to the same polymer carrier. A large number of pre-
clinical trials were conducted in the 80s and the ear-
ly 90s of the 20th century with the objective to opti-
mize the characteristics and prove the safety of poly-
mer carriers and polymer-pharmaceutical linkers 
(12-14). A few technologies influence cancer in ways 
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that drug delivery systems do. The latter enable treat-
ment of cancer with significantly decreased side ef-
fects and provide for new and better chemotherapeu-
tic regimes based on existing  pharmaceuticals (3). 
The possibility for anticancer drugs to be de-
livered locally raises the prospect of improving the 
safety and efficacy of chemotherapy. The medicine 
becomes more effective if put next or directly to the 
target tissue, whereby much higher local concentra-
tion could be achieved (3). One major benefit of poly-
meric pharmaceutical systems is the possibility to at-
tack target tissues by delivering the therapeutic agent 
right to a specific location or organ within the body. 
Polymer conjugates are nanosized multicomponent 
systems developed following clinical studies of an-
titumor substances. They are both applicable as in-
dependent and combined agents. Polymer properties 
determine the circulation time and cellular absorp-
tion speed, decreasing the toxicity of effective cyto-
toxic drugs and imparting favorable physicochemi-
cal properties (e.g. increase in the solubility of lipo-
philic drugs). Unlike most low molecular weight sub-
stances that are prone to systematic distribution and 
fast release in the blood flow, high molecular weight 
compounds, due to their size, demonstrate pro-
longed circulation. Since polymers lack the capaci-
ty to penetrate through cell membranes and to over-
come different biological barriers, their distribution 
in human body is limited (15). As a result, the phar-
macokinetics of bound drug is entirely changed, and 
at the same time its ability to react with substrates 
and receptors is preserved. Immobilized drugs are 
with lower toxicity and completely delayed activity 
as compared to low molecular weight drugs. 
Despite the significant progress in chemother-
apeutics delivery achieved so far, there are a number 
of outstanding problems. In the case of local delivery, 
there is limited drug diffusion within cancer tissues 
and sometimes unwanted drug and polymer carrier 
interactions (3). It is therefore necessary to continue 
the development of drug delivery systems that would 
allow for improvement and widening of therapeutic 
instrumentation in the fight against a wide range of 
tumors.
The use of polymer-pharmaceutical conjugates 
customarily covers the delivery of independent ther-
apeutic agents but multivalence of polymer carriers 
allows for their application also for drug delivery in 
various combinations. It is an outstanding therapeu-
tic option, as it is getting more and more clear that 
multiagent therapy is preferred to monoagent ther-
apy in treatment and prevention of diseases such as 
cancer (16). Currently, only a few study groups sug-
gest the use of polymer carriers for the delivery of 
combined drugs (17-19). Increasing number of water-
soluble polymers are used as macromolecular part-
ners for binding low molecular weight drugs.
APPLICATION OF POLYMERS AS 
CARRIERS OF BIOLOGICALLY AC-
TIVE SUBSTANCES 
In order to be selected as a carrier of drug sub-
stance, a polymer should meet a number of require-
ments: biocompatibility, non-immunogenicity, non-
toxicity, biodegradability or a suitable molecular 
mass – conformed to the renal permeability, pres-
ence of suitable reactive functional groups for bind-
ing with the given drug. An important parameter of 
polymer-pharmaceutical conjugates is the drug re-
lease from the polymer carrier. A wide range of poly-
mers have wide application, such as polyethylene gly-
cols (1,15,20-32), polyesters (33), polyether-polyesters 
(34), peptides (35,36), polyglutamic acid (37,38), hy-
aluronic acid (39-41), polyphosphoesters (32,42,43). 
An important class of phosphorus-containing 
polymers are poly(alkylene Н-phosphonate)s due to 
their diverse reaction mechanism, which enables in-
troduction of different functional groups and bind-
ing with biologically active agents. Over the last 
years, there is a substantial increase in the number 
of scientific publications related to the synthesis and 
application of polyphosphoesters as carriers of bio-
logically active agents, including the radioprotectors 
2-aminoethantiol (44) and WR2721 (45); the multi-
functional alkylating agent bendamustine (46); AZT, 
the effective drug for treatment of HIV (47).
The development of amphiphilic copolymers 
applicable for physical immobilization of hydropho-
bic drugs has generated a great interest. Non-cova-
lent interactions underlie numerous natural pro-
cesses. One of the most important driving forces 
in forming biomacromolecule associates is the for-
mation of a hydrogen bond, which also plays a sig-
nificant role in the association of synthetic poly-
mers. In water solutions, proton acceptor poly-
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mers could be associated with proton donor poly-
mers (48). Promising carriers for physical immobili-
zation (by means of hydrogen bonds) are polyphos-
phoesters (46,49,50). Poly(hydroxyoxyethylene phos-
phate)s are biodegradable, biocompatible, water-sol-
uble and low-toxic polymers (15). Chemotherapeu-
tic agents with phosphate structures would interact 
preferentially with tumor cells (51). Moreover, de-
phosphorylation often takes place more easily in tu-
mor cells compared to normal cells (52). Studies per-
formed on experimental animals demonstrate that 
the polymer poly(hydroxyoxyethylene phosphate) 
does not show toxic effects after intravenous injec-
tion with a dose of 1000 mg/kg body weight. Synthe-
sized polymer pharmaceutical formulations based 
on poly(hydroxyoxyethylene phosphate) and the low 
molecular weight drug paclitaxel show 4000 times 
higher solubility of the drug. The results of biostud-
ies with a polymer complex of paclitaxel performed 
on experimental animals showed decrease of the an-
titumor drug characteristic effect of body weight 
reduction. Such results lead to the conclusion that 
poly(hydroxyoxyethylene phosphate)s could be suc-
cessfully considered as multifunctional carriers of 
drug substances (53).
CONCLUSION
Modern medicine is facing the challenge of de-
riving maximum therapeutic benefit in the develop-
ment of new strategies for treating different kinds 
of tumors. The optimism that we could expect even 
more complex polymers as a new and significant 
supplement to cancer control approaches used so far 
is entirely justified. The achievements made as a re-
sult of numerous studies (improved water-solubility 
of lipophilic drugs and considerably decreased tox-
ic side effects) give grounds for future development 
of polymeric pharmaceutical forms in order to im-
prove the treatment quality and efficacy for millions 
of patients.
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